文献速递遗传性与小管间质肾病

白细胞介素-37:常染色体显性多囊肾病的新治疗靶点

Interleukin-37: a new therapeutic target in autosomal dominant polycystic kidney disease.
PubMed 文献 · Kidney Int · 2024-01-01

常染色体显性多囊肾病(ADPKD)虽为遗传性肾脏病,但肾脏免疫微环境在疾病进展和严重程度中起关键作用。Zylberberg等在本期发表的研究显示,白细胞介素-37通过激活肾巨噬细胞中的干扰素信号通路抑制ADPKD起始,提示其作为潜在免疫调节疗法的可能。

要点

  • ADPKD进展受肾脏免疫微环境影响
  • IL-37激活肾巨噬细胞干扰素信号
  • IL-37抑制ADPKD起始,具治疗潜力

核心结论

  • 白细胞介素-37通过激活肾巨噬细胞干扰素信号抑制ADPKD起始,是潜在免疫调节治疗靶点。

研究设计与样本

  • Zylberberg等在当期发表的研究,具体设计与样本量原文未报告。

主要发现

  • 白细胞介素-37激活肾巨噬细胞中的干扰素信号通路。
  • 该信号激活抑制ADPKD的起始。

临床怎么用

  • 提示白细胞介素-37可作为ADPKD的潜在免疫调节疗法方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autosomal dominant polycystic kidney disease (ADPKD) has long been considered a genetic renal disorder, but emerging evidence suggests that the immune microenvironment within the kidney plays a pivotal role in disease progression and severity. In recent years, the previously obscure cytokine interleukin-37 has proved a strong inhibitor of innate immunity in multiple disease models. However, its role in ADPKD has not received scrutiny. In a provocative study published in the current issue, Zylberberg et al. show that interleukin-37 activates interferon signaling in renal macrophages, which inhibits ADPKD initiation. This finding identifies interleukin-37 as a potential viable immunomodulatory therapy for ADPKD.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Yang B, Crowley SD. Interleukin-37: a new therapeutic target in autosomal dominant polycystic kidney disease. Kidney Int. 2024. PMID: 38519230. doi:10.1016/j.kint.2024.01.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。